

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



聯康集團

Uni-Bio Science

**UNI-BIO SCIENCE GROUP LIMITED**

**聯康生物科技集團有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 0690)**

## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”).

The board (“**Board**”) of directors of Uni-Bio Science Group Limited (“**Company**”, together with its subsidiaries, the “**Group**”) announces that on 2 April 2020, the Company has granted share options (“**Options**”) to eligible persons (consist of eligible grantee and eligible employees of the Group) under the share option scheme adopted by the Company on 28 September 2016 to subscribe for a total of 70,780,000 ordinary shares of the Company (“**Shares**”) were granted. The followings are the details of the Options granted:

Date of grant	:	2 April 2020
Total number of Shares to be issued upon exercise in full of the Options granted	:	70,780,000
Exercise price of Options granted	:	HK\$0.154 per Share
Closing price of the Shares on the date of grant	:	HK\$0.151 per Share
The average closing price of the Shares for the five business days immediately preceding the date of grant	:	HK\$0.154 per Share
Validity period of the Options	:	From 2 April 2020 to 1 April 2030

\* For identification purpose only

- Vesting period of the Options : (a) Of the 35,780,000 Options granted to eligible employees:
- (i) 11,926,667 Options are vested immediately on 2 April 2020;
  - (ii) 11,926,667 Options are to be vested on 2 April 2021; and
  - (iii) 11,926,666 Options are to be vested on 2 April 2022.
- (b) Of the 35,000,000 Options granted to the eligible grantee:
- (i) 10,000,000 Options are to be vested on 1 January 2022 and conditional upon the achievement or attainment of certain business or commercial milestone of the Group;
  - (ii) 5,000,000 Options are to be vested on 1 January 2022 and conditional upon the achievement or attainment of certain business or commercial milestone of the Group; and
  - (iii) 20,000,000 Options are to be vested conditional upon the achievement or attainment of certain business or commercial milestone of the Group.

None of the grantees is a director, chief executive or substantial shareholder of the Company, or any of their respective associates (as defined in the Listing Rules).

On behalf of the Board  
**Uni-Bio Science Group Limited**  
**Kingsley Leung**  
*Chairman*

Hong Kong, 2 April 2020

*As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman) and Mr. Zhao Zhi Gang; one non-executive director, Mr. Yau Kwok Wing Tony; and three independent non-executive directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.*